Spicy Pickle Up & Running

Before I forget, I want to remind you about the Spicy Pickle's (OTCBB: SPKL) web video available simply by clicking the nearby image. From the feedback we've gotten so far, the short video has been very helpful for investors, adding any remaining details we couldn't get to in Saturday's profile. Remember, it's only a small investment of your time (the video is less than 10 minutes long), but could be one of the best investments you make all year. 

Anyway, here we are - two days after we launched our coverage. In a nutshell, SPKL is off to a great start. 

When I saw the stock gap higher on Monday morning, I wasn't sure what to think. I don't mind gaps...I don't particularly want them, but I don't mind them. My worry was whether or not SPKL was going to take off and instantaneously be out of reach for anybody who wanted in. Fortunately, the stock found a comfort level between 75 and 85 cents on Monday, and that range was even smaller (and more bullish) on Tuesday, and it seems as if there's some support around 75 cents.

So where to from here? 

I have to say I'm fairly impressed. With Monday's big move higher, I'm sure it was tempting for all those owners who bought shares at 50 cents (or even less than that) to go ahead and lock in a big gain, which would have driven the chart much lower. They didn't though. In fact, we saw a few more buyers pile in today..even more than with Friday's big rally. The stock closed out the trading session slightly higher than yesterday. 

I'd like to see a higher high sometime this week to really add some solidity to the stock's recent run. All things considered though, investors seem quite OK with the big jump so far. As far as the gap is concerned, if it does indeed get closed, I view that as another entry opportunity. At this point, however, I wouldn't be shocked if it never got closed. 
 

	Overstock Overbought?

I don't know whether I should celebrate or gripe. I'm thrilled our Overstock.com (NASDAQ: OSTK) pick from September 7th is already up by more than 20%. I just wish it would have gotten from there to here at a little slower pace. Sound crazy? I don't entirely disagree, but here's my thinking... 

The result of the big, quick move is a very overbought chart, and we were somewhat overbought to begin with. (I'm using stochastics as my overbought indicator.) It's not like being overbought is a sure-fire recipe for a pullback, but it doesn't exactly help. We've also seen a high right around $28.00 over the last three days. Is there something significant about this level? Not that I can tell, but the uptrend seems to be taking a break there all the same. 

So, I think the right way to play it is prepare for the worst, and assume the best.

In this case, even the 'worst' isn't all that bad. I think a slide all the way back to the 38.2% retracement line would be a much-deserved breather. Unless that $26.65 level failed to act as support, it really wouldn't worry me. In fact, it may well be a decent second-chance entry for those so inclined. 

On the other side of the chart, I believe breaking past the short-term ceiling of $28.00 could be a bullish catalyst...at least enough of one to get us up to our target of $30.20.

I mentioned the possibility of ignoring the target and letting it run as long as it could. Based on the speed and size of this gain though, now I'm thinking we should just leave well enough alone, and leave the suggested target as is. If it continues to run past that mark, we can always buy it on a dip later. 
 

	BioCurex Advisor Honored

It's becoming clear why BioCurex (OTCBB: BOCX) is really starting to turn a few heads within the medical community - they have some of the brightest people in the industry involved in their work. 

The latest round of evidence comes from the International Society for Oncodevelopmental Biology and Medicine (ISOBM) conference...the one we were discussing only a few days ago where Abbott Laboratories (NYSE: ABT) finally unveiled their success with BioCurex's RECAF cancer marker. Dr. Stewart Sell, a member of BioCurex's scientific advisory board, was presented with the ISOBM-Abbott award. He was chosen based on his lifetime work in cancer research, immunology, and stem cell research. 

Dr. Sell's background is impressive to say the least, and it was far from the first honor bestowed in him. 

While congratulations are in order, something else now really sticks out thanks to the announcement...BioCurex has a lot of brilliant people on their team. That's nothing new, and certainly isn't the kind of thing that's going to make the stock jump tomorrow. However, I do think it's critical to the long-term success of a stock to have the right leadership in place. (After all, if the biotechnology doesn't work, what's the point?) 

By the way, it's not the first time a BioCurex advisory board member has won the ISOBM-Abbott award. The two gentlemen who discovered the first two ever-known cancer markers are also on BioCurex's scientific advisory board. Coincidence? I doubt it. 

Anyway, here's the complete news release. 
 

	Titan Global - Still Going

It's almost become surreal how rapidly Titan Global (OTCBB: TTGL) is expanding, with its stock in tow. I really hope you got on board when we first suggested it back in January, or at least when we reiterated it in early August. The stock is up about 80% since our first look, and may be on the verge of yet another bullish leg. 

Take a look at the action since the 16th of August. That was not only the market's bottom, but also the beginning of a recovery for TTGL following a huge washout day on the 15th. I plotted some Fibonacci lines starting with those lows, and extended them all the way up to September 6th's peak of $2.20. As long as that first retracement level holds near $1.87 (which it has so far), I think everything is going to be fine. That retracement level is likely to be a factor until.... 

...we see a move past $2.20. TTGL revisited that high again last week, and has toyed with it everyday since then. We've not yet seen a trade above that level, but I feel that we will eventually. Why? This stock has made a habit of stair-stepping its way to higher highs....up, then sideways, up, then sideways. The 20 day moving average seems to be the uptrend's restart point.

The catalyst for this recent push? There's certainly not been a lack of news from Titan, but I think this latest round of buying interest was inspired by the conference all from Thursday, September 20th, and the news from Friday, September 21st. If you missed that press release, basically, Titan Communications is now going to utilize Appco's convenience stores as retail outlets for wireless phones and pre-paid calling cards. That was no surprise - multiple uses of distribution channels has been their goal for quite some time. I think the brunt of the new demand was prompted by the conference call. 

Keep an eye on $2.20...I've just got a feeling.
 

We Value Your Feedback

Got comments, questions or suggestions? Send 'em on over: Email the Editor If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130

Subscribe

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the Small Cap Network Newsletter, simply follow the instructions located at the bottom of every Small Cap Network Newsletter Edition.

Click Here or go to http://www.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://www.smallcapnetwork.com/profile_disclosure.html for our full profiles and http://www.smallcapnetwork.com/short_term_alerts.html for Trading Alerts. 

Larry Isen, the editor and publisher of the OTC Journal, through various entities he controls, has purchased 1,200,441 shares of Spicy Pickle at an average cost of $.2125 per share. These purchases were made in Spicy Pickle private offerings. The aforementioned purchases were made between August of 2005 and August of 2006. In addition, Larry Isen has received 785,000 shares of Spicy Pickle common stock for consulting services. In addition, MarketByte LLC, an entity controlled by Larry Isen, has received a fee of $30,000 cash, and 300,000 newly issued restricted shares for coverage of Spicy Pickle. TGR Group LLC, the publisher of the Small Cap Network, has received $30,000 and 300,000 newly issued restricted shares for coverage of Spicy Pickle. Mr. Isen is an affiliate of TGR Group. In addition, two other individuals affiliated with TGR Group have purchased a total of 300,000 shares at $.25 per share and received an additional 70,000 for consulting services. Current positions of the aforementioned can be found at www.otcjournal.com and www.smallcapnetwork.com in the Spicy Pickle information section. 

TGR Group LLC has been paid a fee of $30,000 cash by Titan General for coverage of the company. In addition, TGR Group LLC has been pledged a fee of 100,000 warrants convertible at $1 into restricted shares by Trilogy Capital for coverage of the company. 

In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock.

From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. 

TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed. 

All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCN is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. 

The profiles, critiques, and other editorial content of SCN may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein. 

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR. 

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.